WILMINGTON, Del. — August 27, 2025 — Leads & Copy — Sarborg Limited has successfully closed a $10 million Seed funding round, led by Corvus Capital, to scale its AI-driven drug development and deploy agents across expanded client portfolios. The company, which integrates mathematical algorithm-led approaches with complementary cybernetics to optimize decision-making processes, has achieved significant commercial and technical milestones since its inception in 2024. The funding will also deepen its intellectual property portfolio and broaden its agentic approach to fields beyond pharmaceuticals.
Sarborg has capitalized on early revenue-generation, executing an initial services agreement with a NASDAQ-listed Pharmaceutical Company, validating its core technologies and a repurposing strategy based on their lead-program drug-signature model. Sarborg has delivered personalized dashboards to clients, providing real-time access to data related to deliverables, research and development oversight, and drug discovery, and built a proprietary portfolio of over 800 disease signatures.
The funding will advance Sarborg’s proprietary AI agents focused on drug repurposing, target identification, and clinical trial optimization, develop novel pharmaceutical IP, transforming underused molecules into novel IP through solid-form engineering and formulation expertise, grow Sarborg’s internal pipeline of pharmaceutical assets for monetization via outlicensing or royalty-based deal structures and expand the client base and revenue-generating service business to fund ongoing innovation and reduce dilution in future rounds.
Following the demand for its seed financing, the Company expects to shortly launch a follow-on Series A financing round to enable Sarborg to scale globally and solidify its position as a category leader in AI-driven agentic innovation.
Investors & Media:
info@sarborg.com
Source: Sarborg Limited
